Advertisement

Topics

Pfizer expects to close Medivation buyout in 3Q

12:18 EDT 23 Sep 2016 | Topix

Pfizer expects to complete its $14 billion buyout of cancer drug developer Medivation in the third quarter following the expiration of a regulatory waiting period. The New York drugmaker has agreed to pay $81.50 per Medivation share, which marked a 21 percent premium to San Francisco-based Medivation's closing price when it was announced in August.

Original Article: Pfizer expects to close Medivation buyout in 3Q

NEXT ARTICLE

More From BioPortfolio on "Pfizer expects to close Medivation buyout in 3Q"

Quick Search
Advertisement